Outlook Therapeutics to Present at the 8th Annual Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase
Outlook Therapeutics (NASDAQ: OTLK), a biopharmaceutical company specializing in bevacizumab treatments for retina diseases, announced its participation in the 8th Annual OIS Retina Innovation Summit. The company's CEO, Bob Jahr, will present during the Innovation Showcase session on July 29, 2025, from 8:35 – 9:35 AM PT in Long Beach, California.
Outlook Therapeutics (NASDAQ: OTLK), un'azienda biofarmaceutica specializzata in trattamenti a base di bevacizumab per le malattie retiniche, ha annunciato la sua partecipazione all'8° Summit Annuale di Innovazione OIS Retina. Il CEO dell'azienda, Bob Jahr, presenterà durante la sessione Innovation Showcase il 29 luglio 2025, dalle 8:35 alle 9:35 AM PT a Long Beach, California.
Outlook Therapeutics (NASDAQ: OTLK), una empresa biofarmacéutica especializada en tratamientos con bevacizumab para enfermedades de la retina, anunció su participación en la 8ª Cumbre Anual de Innovación OIS Retina. El CEO de la compañía, Bob Jahr, presentará durante la sesión Innovation Showcase el 29 de julio de 2025, de 8:35 a 9:35 AM PT en Long Beach, California.
Outlook Therapeutics (NASDAQ: OTLK)는 망막 질환을 위한 베바시주맙 치료에 특화된 생명공학 회사로, 제8회 연례 OIS 망막 혁신 서밋에 참여한다고 발표했습니다. 회사의 CEO인 Bob Jahr가 2025년 7월 29일 오전 8시 35분부터 9시 35분까지(태평양 시간) 캘리포니아 롱비치에서 열리는 Innovation Showcase 세션에서 발표할 예정입니다.
Outlook Therapeutics (NASDAQ : OTLK), une société biopharmaceutique spécialisée dans les traitements au bevacizumab pour les maladies de la rétine, a annoncé sa participation au 8e Sommet annuel d'innovation OIS Retina. Le PDG de l'entreprise, Bob Jahr, présentera lors de la session Innovation Showcase le 29 juillet 2025, de 8h35 à 9h35 PT à Long Beach, Californie.
Outlook Therapeutics (NASDAQ: OTLK), ein biopharmazeutisches Unternehmen, das sich auf Bevacizumab-Behandlungen für Netzhauterkrankungen spezialisiert hat, gab seine Teilnahme am 8. jährlichen OIS Retina Innovation Summit bekannt. Der CEO des Unternehmens, Bob Jahr, wird während der Innovation Showcase-Sitzung am 29. Juli 2025 von 8:35 bis 9:35 Uhr PT in Long Beach, Kalifornien, präsentieren.
- None.
- None.
ISELIN, N.J., July 24, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it will present at the 8th Annual OIS Retina Innovation Summit being held on July 29, 2025 in Long Beach CA.
Details for the presentations are as follows:
Session: Innovation Showcase
Presenter: Bob Jahr, Chief Executive Officer of Outlook Therapeutics
Date and Time: Tuesday, July 29, 2025, 8:35 – 9:35 AM PT
For more information and to register for this event, please visit OIS Retina @ ASRS.
About the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase
Launched in 2009, the Ophthalmology Innovation Summit serves to showcase novel therapies in development for unmet needs in ophthalmic disease and vision disorders, bringing together entrepreneurs, ophthalmic start-up companies, clinical thought leaders, industry executives and investment professionals to facilitate an exchange of information and connections to drive innovation in the retina, anterior segment, and optometry.
About Outlook Therapeutics, Inc.
Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma) to enhance the standard of care for bevacizumab for the treatment of retina diseases. LYTENAVA™ (bevacizumab gamma) is the first ophthalmic formulation of bevacizumab to receive European Commission and MHRA Marketing Authorization for the treatment of wet AMD. Outlook Therapeutics commenced commercial launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK as a treatment for wet AMD.
In the United States, ONS-5010/LYTENAVA™ (bevacizumab-vikg) is investigational, and a BLA has been resubmitted to the FDA. If approved in the United States, ONS-5010/LYTENAVA™, would be the first approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD.
Investor Inquiries:
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 908.824.0775
OTLK@jtcir.com
FAQ
When is Outlook Therapeutics (OTLK) presenting at the OIS Retina Innovation Summit 2025?
Who will be presenting for Outlook Therapeutics (OTLK) at the OIS Retina Summit?
What is Outlook Therapeutics' (OTLK) main focus as a company?
Where is the 8th Annual OIS Retina Innovation Summit being held?
